[go: up one dir, main page]

BR0317780A - Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas - Google Patents

Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas

Info

Publication number
BR0317780A
BR0317780A BR0317780-7A BR0317780A BR0317780A BR 0317780 A BR0317780 A BR 0317780A BR 0317780 A BR0317780 A BR 0317780A BR 0317780 A BR0317780 A BR 0317780A
Authority
BR
Brazil
Prior art keywords
treating hemorrhoids
thrombolytically
proteins
rectal administration
suppository formulation
Prior art date
Application number
BR0317780-7A
Other languages
English (en)
Other versions
BRPI0317780B1 (pt
BRPI0317780B8 (pt
Inventor
Maria Acelia Marrero Miragaya
Ana Aguilera Barreto
Lisette Gonzalez Chavez
Eduardo Martinez Diaz
Beatriz Torrez Cabrera
Karelia Cosme Diaz
Milesa Yeni Sarmiento Mayea
Luciano Francisco Hern Marrero
Beatriz Tamargo Santos
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BR0317780A publication Critical patent/BR0317780A/pt
Publication of BRPI0317780B1 publication Critical patent/BRPI0317780B1/pt
Publication of BRPI0317780B8 publication Critical patent/BRPI0317780B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO NA FORMA DE SUPOSITóRIO PARA A ADMINISTRAçãO RETAL, MéTODO PARA O TRATAMENTO DE HEMORRóIDAS, E USO DE PEPTìDEOS E PROTEìNAS COM AçãO TROMBOLìTICA PARA O TRATAMENTO DE HEMORRóIDAS". Formulações farmacêuticas em forma de supositórios que contém agentes com ação trombolítica capazes de penetrar na mucosa retal para o tratamento da enfermidade hemorroidal aguda e/ou de origem trombótica.
BRPI0317780A 2002-12-27 2003-12-22 uso de supositório de estreptoquinase com ação trombolítica BRPI0317780B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20020336A CU23203A1 (es) 2002-12-27 2002-12-27 Formulaciones que contienen agentes de accion trombolitica para su administracion por via rectal
CU2002/0336 2002-12-27
PCT/CU2003/000020 WO2004058219A1 (es) 2002-12-27 2003-12-22 Formulaciones para administrar por vía rectal agentes con acción trombolítica

Publications (3)

Publication Number Publication Date
BR0317780A true BR0317780A (pt) 2005-11-22
BRPI0317780B1 BRPI0317780B1 (pt) 2018-11-21
BRPI0317780B8 BRPI0317780B8 (pt) 2021-05-25

Family

ID=40091670

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0317780A BRPI0317780B8 (pt) 2002-12-27 2003-12-22 uso de supositório de estreptoquinase com ação trombolítica

Country Status (19)

Country Link
US (1) US10213379B2 (pt)
EP (1) EP1576951B1 (pt)
JP (1) JP2006512374A (pt)
KR (1) KR100804013B1 (pt)
CN (1) CN100335128C (pt)
AR (1) AR042646A1 (pt)
AT (1) ATE409460T1 (pt)
AU (1) AU2003291916B2 (pt)
BR (1) BRPI0317780B8 (pt)
CA (1) CA2527572C (pt)
CU (1) CU23203A1 (pt)
DE (1) DE60323874D1 (pt)
DK (1) DK1576951T3 (pt)
ES (1) ES2315537T3 (pt)
MX (1) MXPA05007006A (pt)
MY (1) MY142241A (pt)
PT (1) PT1576951E (pt)
WO (1) WO2004058219A1 (pt)
ZA (1) ZA200505399B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660429B (zh) * 2005-01-10 2011-09-07 王振军 基质金属蛋白酶（mmp）抑制剂用于治疗痔的新用途
CN100364610C (zh) * 2005-12-12 2008-01-30 北京大学 提高蚓激酶口服吸收生物利用度的方法
CN102091326B (zh) * 2009-12-15 2013-04-03 上海凯茂生物医药有限公司 治疗因肛门皮下的静脉丛发生扩大或曲张所引发的痔类疾病的经皮给药制剂及制备方法
CN102552916B (zh) * 2010-12-09 2014-04-23 上海凯茂生物医药有限公司 水杨酸钠的新用途
EP3115037B1 (de) * 2015-07-08 2018-08-15 Dr. Falk Pharma Gmbh Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
US5098707A (en) * 1989-07-31 1992-03-24 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5885967A (en) * 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US5837688A (en) * 1996-11-27 1998-11-17 Gelfand; Mathew I. Use of thrombolytic reagents for prevention of vascular disease
EP1021195A1 (en) * 1997-10-07 2000-07-26 The Regents Of The University Of California Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine
AU7965000A (en) * 1999-09-27 2001-04-30 Jun-Suk Oh Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same

Also Published As

Publication number Publication date
CN100335128C (zh) 2007-09-05
AR042646A1 (es) 2005-06-29
MXPA05007006A (es) 2005-08-18
ZA200505399B (en) 2006-04-26
DE60323874D1 (de) 2008-11-13
ES2315537T3 (es) 2009-04-01
PT1576951E (pt) 2009-01-09
WO2004058219A1 (es) 2004-07-15
CA2527572C (en) 2010-03-30
AU2003291916A1 (en) 2004-07-22
BRPI0317780B1 (pt) 2018-11-21
AU2003291916B2 (en) 2007-03-08
ATE409460T1 (de) 2008-10-15
KR100804013B1 (ko) 2008-02-18
EP1576951A1 (en) 2005-09-21
EP1576951B1 (en) 2008-10-01
DK1576951T3 (da) 2009-02-02
BRPI0317780B8 (pt) 2021-05-25
CN1738602A (zh) 2006-02-22
MY142241A (en) 2010-11-15
CU23203A1 (es) 2007-05-18
US10213379B2 (en) 2019-02-26
US20070166298A1 (en) 2007-07-19
JP2006512374A (ja) 2006-04-13
KR20050088219A (ko) 2005-09-02
CA2527572A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
NO964527D0 (no) Blandinger omfattende DNA-ödeleggende midler og P53
BR9806747A (pt) Sistema terapêutico transdérmico.
BR9812965A (pt) Métodos para tratamento de estados hipercoaguláveis ou deficiência de proteìna c adquirida
BRPI0411924A (pt) métodos e dispositivos para oclusão de lúmens de corpo e/ou para fornecimento de agentes terapêuticos
ECSP024352A (es) Nueva composicion farmaceutica
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
MX9203278A (es) Pastilla de liberacion sustentada que comprende loratadina, ibuprofen y pseudoefedrina.
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
BR9916694A (pt) Composição de lenço facial e método de uso parasequestração de irritantes cutâneos de secreçãonasal
BR0113400A (pt) Método para seleção de peptìdeo
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
SE9404196D0 (sv) New antithrombotic formulation
AR025001A1 (es) Formulacion de sal comun y moxifloxacina
BRPI0208411B8 (pt) composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto
BR9807523A (pt) Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids.
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
ATE451934T1 (de) Pharmazeutische zusammensetzung zur behandlung von rhinitiden
BR0101486A (pt) Composições farmacêuticas de uso tópico, aplicadas no tratamento de lesões de pele e/ou mucosas; uso das composições no tratamento de lesões de pele e/ou mucosas e uso de compostos no tratamento de lesões de pele e/ou mucosas
BR0317780A (pt) Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas
BR0204573A (pt) Composição para redução da irritação cutânea enzimática
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
SE0001916D0 (sv) Novel formulation

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/02 , A61K 38/49

Ipc: A61K 9/02 (2006.01), A61K 38/49 (2006.01), A61K 38

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.